

1 **Shared genetic factors do not account for the observed co-occurrence of depression and**
2 **autoimmune diseases in the UK Biobank.**

3 Kylie P Glanville¹, Jonathan R I Coleman^{1,2}, Paul F O'Reilly³, *James Galloway⁴, *Cathryn M
4 Lewis^{1,2,5}

5 *Contributed equally and share senior authorship.

6 1. Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
7 Neuroscience, King's College London, London, GB

8 2. NIHR Biomedical Research Centre, South London and Maudsley NHS Trust, King's College
9 London, London, GB

10 3. Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, US

11 4. Department of Inflammation Biology, King's College London, London, GB

12 5. Department of Medical & Molecular Genetics, King's College London, London, GB

13

14 **Address correspondence to** Kylie P. Glanville, kylie.glanville@kcl.ac.uk; Social, Genetic and
15 Developmental Psychiatry Centre; Institute of Psychiatry, Psychology & Neuroscience; King's
16 College London, de Crespigny Park, London SE5 8AF; UK.

17 Abstract

18 **Background:** Epidemiological studies have shown increased comorbidity between depression
19 and autoimmune diseases. The mechanisms driving the comorbidity are poorly understood, and
20 a highly powered investigation is needed to understand the relative importance of shared genetic
21 influences. We investigated the evidence for pleiotropy from shared genetic risk alleles between
22 these traits in the UK Biobank (UKB).

23 **Methods:** We defined autoimmune and depression cases using information from hospital
24 episode statistics, self-reported conditions and medications, and mental health questionnaires.
25 Pairwise comparisons of depression prevalence between autoimmune cases and controls, and
26 vice-versa, were performed. Cross-trait polygenic risk score (PRS) analyses were performed to
27 test for pleiotropy, i.e. testing whether PRS for depression could predict autoimmune disease
28 status, and vice-versa.

29 **Results:** We identified 28k cases of autoimmune diseases (pooling across 14 traits), and 65k cases
30 of depression. The prevalence of depression was significantly higher in autoimmune cases
31 compared to controls, and vice-versa. PRS for myasthenia gravis and psoriasis were significantly
32 associated with depression case-status ($p < 5.2 \times 10^{-5}$, $R^2 \leq 0.04\%$). PRS for depression were
33 significantly associated with case-status for coeliac disease, inflammatory bowel disease,
34 psoriasis, psoriatic arthritis, rheumatoid arthritis and type 1 diabetes ($p < 5.8 \times 10^{-5}$, R^2 range 0.06%
35 to 0.27%).

36 **Conclusions:** Consistent with the literature, depression was more common in individuals with
37 autoimmune diseases compared to controls, and vice-versa, in the UKB. PRS showed some
38 evidence for involvement of shared genetic factors, but the modest R^2 values suggest that shared
39 genetic architecture accounts for only a small proportion of the increased risk across traits.

40 Introduction

41 There is substantial evidence that individuals with a history of autoimmune disease are at greater
42 risk for developing depression¹⁻⁴, and that a history of depression increases risk for developing
43 autoimmune diseases^{5,6}. The mechanisms driving the bi-directional relationship are poorly
44 understood, but one contributory factor may be that these diseases share biological pathways.
45 We and others have previously shown that there is no strong evidence for the involvement of
46 Human Leukocyte Antigen (HLA) alleles in risk for depression, suggesting that the Major
47 Histocompatibility Complex (MHC) does not harbor shared risk for depression and autoimmune
48 diseases⁶⁻⁸. However, genetic risk for autoimmune diseases occurs across the genome⁹, and
49 pleiotropic effects outside the MHC may be involved in shared risk for depression and
50 autoimmune diseases.

51 Few studies have investigated evidence for genome-wide pleiotropy between depression and
52 autoimmune diseases. Euesden, et al.¹⁰ found no evidence for association between polygenic risk
53 scores (PRS) for depression and risk for rheumatoid arthritis, or vice-versa. The Psychiatric
54 Genomics Consortium (PGC) indicated no evidence for significant genetic correlations (rG)
55 between depression and nine autoimmune diseases; the strongest correlation observed was
56 between depression and inflammatory bowel disease ($rG = .07$, $p = .06$)¹¹. Recently, Liu, et al.⁶
57 found no association between PRS for mental health disorders and risk for autoimmune diseases,
58 and only a weak association between PRS for autoimmune diseases and risk for mental health
59 disorders.

60 In this study we extend previous work, leveraging the UK Biobank (UKB) to test for pleiotropy
61 between depression and autoimmune diseases with PRS methodology. Given the challenge of
62 reliably defining complex disease traits using large-scale data, we take two approaches to
63 defining autoimmune diseases and depression. We classified liberally-defined cases, based on a
64 single item endorsing diagnosis with an autoimmune disease, and then strictly-defined cases,
65 based on multiple items. We take a similar approach to classifying depression by requiring a
66 greater number of endorsements in strictly-defined cases than liberally-defined cases. Liberally-
67 defined cases increase the sample size, while strictly-defined cases will reduce the rate of
68 misclassification. We perform cross-trait PRS analyses, testing for association between PRS for
69 autoimmune diseases and depression, and vice-versa. Motivated by the observation of sex-
70 dependent genetic correlations between schizophrenia and autoimmune diseases¹², and by
71 higher prevalence in females of both depression and autoimmune diseases, we stratified PRS
72 analyses by sex. Our study is one of the largest to explore evidence for pleiotropy between
73 depression and autoimmune diseases and elucidates the contribution of shared genetic
74 influences to the observed comorbidity.

75 Methods

76 Participants

77 The UKB is a prospective health study of 500,000 individuals in the United Kingdom. Participants
78 were identified through NHS patient registers if they were aged 40-69 during the recruitment
79 phase (2006-2010) and living in proximity to an assessment centre. Participants attended a
80 baseline assessment and contributed health information via touchscreen questionnaires and
81 verbal interviews¹³. Subsets of participants completed repeat assessments: instance 1) n = 20,335
82 between 2012-2013; instance 2) n = 42,961 (interview) and n = 48,340 (touchscreen) in 2014;
83 and instance 3) n = 2,843 (interview) and n = 3,081 (touchscreen) in 2019. Participant data are
84 linked to Hospital Episode Statistics (HES) containing information on episodes of inpatient
85 hospital care. Episodes are coded at admission using the International Classification of Diseases,
86 10th Revision¹⁴ (ICD-10). Inpatients are assigned one primary code (reason for admission) and a
87 variable number of secondary codes. Additional data are available for psychiatric phenotyping,
88 including an online Mental Health Questionnaire (MHQ) completed by 157,366 participants in
89 2017¹⁵. The UKB received ethical approval from the North West - Haydock Research Ethics
90 Committee (reference 16/NW/0274). Participants provided electronic signed consent at
91 recruitment¹³.


92 Autoimmune phenotyping

93 Guided by studies that investigated the epidemiological relationship between autoimmune
94 diseases and depression^{1,5} we identified cases for fourteen autoimmune diseases: pernicious
95 anemia (PA), autoimmune thyroid disease (ATD), type 1 diabetes (T1D), multiple sclerosis (MS),
96 myasthenia gravis (MG), coeliac, inflammatory bowel disease (IBD; includes crohn's disease and
97 ulcerative colitis), psoriasis, ankylosing spondylitis (AS), polymyalgia rheumatica/giant cell
98 arteritis (PR/GCA), psoriatic arthritis (PsA), rheumatoid arthritis (RA), sjögren syndrome (SS), and
99 systemic lupus erythematosus (SLE).

100 Two sources of information were used to define autoimmune cases and controls. (1) HES: primary
101 and secondary ICD-10 diagnoses recorded between April 1997 to October 2016 were identified
102 from the UKB Data Portal Record Repository. (2) Verbal interview: we used participants'
103 responses at baseline or instance 1 or 2 to determine self-endorsed medical conditions (past and
104 current) and self-endorsed prescription medications (current). ICD-10 codes, self-endorsed
105 conditions and medications used to define each autoimmune disease are listed in the
106 Supplementary Material.

107 We took two approaches to defining autoimmune cases (Figure 1). To increase sample size, we
108 created 'possible' cases, comprising participants with an ICD-10 diagnosis or a self-endorsed
109 condition. To increase validity, we used multiple observations to create 'probable' cases.
110 Participants were coded as probable cases if at least two of ICD-10 diagnosis, self-endorsed
111 condition or medication were observed. More than one ICD-10 diagnosis for the corresponding

112 autoimmune disease was also sufficient. A set of autoimmune controls was defined from
113 participants with no ICD-10 diagnoses, self-endorsed conditions or medications for all fourteen
114 autoimmune diseases. A single set of controls was used for all autoimmune diseases, given the
115 known comorbidity between them.



116
117 Figure 1: Autoimmune phenotyping approach. Cases are included in possible or probable if they fall within a
118 shaded area. Autoimmune medication was used as a confirmatory, but not a primary source of information,
119 because several medications are not disease-specific.

120

121 Depression phenotyping

122 We created two depression case groups: strictly-defined cases termed 'stringent depression' and
123 liberally-defined cases termed 'any depression'. We have previously shown that SNP-based
124 heritability increases with multiple endorsements of depression¹⁶. We therefore classified

125 'stringent depression' as participants endorsing at least three of the following depression
126 measures: ICD-10 diagnoses (F32-F33.9); self-reported depression; self-reported antidepressant
127 usage; single or recurrent depression (defined by Smith, et al.¹⁷ from responses to a touchscreen
128 questionnaire completed at baseline by 172,751 participants); or answered 'yes' to the
129 touchscreen questionnaire: "Have you ever seen a GP/psychiatrist for nerves, anxiety, tension or
130 depression?".

131 We classified 'any depression' as participants who endorsed two or more depression measures,
132 or if they met criteria for lifetime depression in the Composite International Diagnostic Interview
133 (CIDI) assessed in the MHQ¹⁵. We classify cases defined from CIDI alone as 'any depression' not
134 as 'stringent depression' because we previously observed lower SNP-based heritability in this
135 group ($h^2_{\text{SNP}} = 11\%$, SE = 0.008) compared to cases defined by three or more non-CIDI measures
136 of depression ($h^2_{\text{SNP}} = 19\%$, SE = 0.018)¹⁶.

137 Depression cases were screened for schizophrenia and bipolar according to any indication: ICD-
138 10 diagnoses (F20-29, F30-31.9, F34-39); self-endorsed conditions (schizophrenia, mania, bipolar
139 disorder or manic depression) or self-endorsed antipsychotic usage reported at baseline or
140 instance 1 or 2; Bipolar Type I (Mania) or Bipolar Type II (Hypomania) according to the criteria
141 adopted by Smith, et al.¹⁷; or indications of psychosis endorsed in the MHQ. A single set of
142 depression controls was defined from participants who did not meet the criteria for depression,
143 schizophrenia or bipolar.

144 Detail on the derivation of each indication of depression, schizophrenia and bipolar can be found
145 in Supplementary Materials from our previous publication¹⁶.

146 Genetic quality control (QC)

147 The UKB performed preliminary QC on genotype data assayed for all participants¹³. Using genetic
148 principal components (PCs) provided by the UKB, we performed 4-means clustering on the first
149 two PCs to identify and retain individuals of European ancestry. QC was then performed using
150 PLINK v1.9¹⁸ to remove: variants with missingness > 0.02 (before individual QC), individuals with
151 missingness > 0.02, individuals whose self-reported sex was discordant from their genetic sex,
152 variants with missingness > 0.02 (after individual QC), variants departing from Hardy-Weinberg
153 Equilibrium ($p < 10e-8$), and variants with minor allele frequency (MAF) < 0.01. Relatedness
154 kinship estimates provided by the UKB were used to identify pairs of related individuals (KING r^2
155 > 0.044)¹⁹ and the GreedyRelated²⁰ algorithm used to remove one individual from each pair,
156 preferentially retaining individuals that survived QC. FlashPCA2²¹ was used to generate PCs for
157 the sub-set of individuals of European ancestry surviving QC.

158 Statistical analyses

159 We summarised sociodemographic data taken at baseline assessment: age, sex, socio-economic
160 status (SES), body mass index (BMI) and current smoking status. We tested for significant
161 differences in sociodemographic variables between cases and controls using Welch Two Sample
162 t-tests in R v3.6²². We tested for significant differences in: 1) the prevalence of depression in

163 autoimmune cases compared to autoimmune controls, and 2) the prevalence of autoimmune
164 diseases in depression cases compared to depression controls. These tests were performed for
165 both probable/possible autoimmune cases and stringent/any depression, using 2-sample tests
166 for equality of proportions in R v3.6²².

167 [Summary statistics for autoimmune diseases and depression](#)

168 We identified genome-wide association studies (GWAS) with publicly-available summary
169 statistics for eight of the fourteen autoimmune diseases: coeliac²³, IBD²⁴, MS²⁵, MG²⁶, psoriasis²⁷,
170 PsA²⁸, RA²⁹, and SLE³⁰ (Supplementary Table 1). Summary statistics from GWAS using the
171 Immunochip were excluded as it does not provide genome-wide coverage. For Major Depressive
172 Disorder (MDD), we used summary statistics from Wray, et al.¹¹, excluding UKB. QC was
173 performed on summary statistics to remove variants within the Major Histocompatibility
174 Complex (28.8 to 33.7 Mb), and variants in linkage disequilibrium ($r^2 > 0.1$) with the lead variant
175 within a 250kb region.

176 [Polygenic risk score \(PRS\) analyses](#)

177 PRS analyses were conducted using the PRSice-2 software³¹. To validate our phenotyping
178 approach, we tested for association between PRS for eight autoimmune diseases and case-
179 control status for the corresponding autoimmune diseases (possible and probable cases), and
180 between PRS for MDD and case-control status for depression (any and stringent).

181 To investigate pleiotropy between autoimmune diseases and depression we performed cross-
182 trait analyses, testing for association between 1) PRS for eight autoimmune diseases and case-
183 control status for depression (any and stringent cases); and 2) PRS for MDD and case-control
184 status for fourteen autoimmune diseases (possible and probable cases). To test for sex-specific
185 effects, we performed cross-trait analyses in males and females separately.

186 For each test, PRS constructed at eight p-value thresholds (P_T ; 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5
187 and 1.0) were regressed on case-control status using logistic regression, adjusting for the
188 following covariates: six PCs, genotyping batch, and assessment centre ($n=128$ variables). We
189 report p-values at the optimal P_T for each test of association. To control for multiple testing across
190 P_T (x8), and across tests of association (autoimmune PRS (x8) predicting any/stringent depression
191 (x2) in men and women (x2), $n=32$; and MDD PRS predicting possible/probable (x2) autoimmune
192 diseases (x14) in men and women (x2), $n=56$), a Bonferroni correction was applied to give a p-
193 value threshold for significance of 7.1×10^{-5} ($0.05/704$ tests, $704 = 8 \times (32+56)$). Where sex-specific
194 associations were observed, sensitivity analyses were conducted to account for different sample
195 sizes between sexes. We tested for interactions between sex and PRS (at the optimal P_T from sex-
196 specific tests) in the full sample (Phenotype \sim sex + PRS + sex*PRS + covariates). We report R^2
197 estimates transformed to the liability scale using the following population prevalences for
198 outcome traits: PA=0.1%³², ATD=2%³³, T1D=0.3%³⁴, MS=0.1%²⁵, MG=0.02%³⁵, coeliac=1%²³,
199 IBD=0.5%²⁴, psoriasis=2%³⁶, AS=0.55%³⁷, PR/GCA= 0.85%³⁸, PsA=0.5%²⁸, RA=1%³⁹, SS=0.7%⁴⁰,
200 SLE=0.1%⁴¹ and MDD=15%¹¹.

201 AVENGEME⁴² was used to estimate power to detect cross-trait PRS associations, assuming
202 varying degrees of genetic correlation (r_G) between corresponding traits (r_G 0.01 to 0.5). Power
203 was estimated for cross-trait analyses where summary statistics for both traits were publicly
204 available, such that SNP-based heritability (required for AVENGEME) could be estimated using
205 Linkage Disequilibrium Score Regression⁴³ (Supplementary Figure 5). Power was estimated using
206 PRS at the optimal P_T identified in cross-trait association tests, and liberally-defined sample sizes.
207 Parameters used to estimate power are given in Supplementary Tables 6 and 7.

208 Results

209 A total of 28,479 individuals were identified as possible cases across fourteen autoimmune
210 diseases, and a sub-set of 16,824 (59.1%) met the stringent criteria for probable cases (refer
211 Supplementary Material for representation of the overlap between criteria used to define cases).
212 65,075 individuals met the criteria for any depression, 14,625 of whom met the criteria for
213 stringent depression. Sociodemographic characteristics for autoimmune and depression cases
214 and controls are summarised in Table 1. Overall, autoimmune and depression case groups
215 contained a higher proportion of females, had lower SES, higher smoking prevalence, and higher
216 BMI than their respective control groups, (N = 324,074 autoimmune controls, N = 232,552
217 depression controls, all p-values < 5×10^{-21} in pairwise comparisons).

218 Table 1: Sociodemographic information for autoimmune and depression cases and controls. Pop. Prev. = population prevalence estimate. UKB Prev. = prevalence of cases
 219 in the UKB as a proportion of autoimmune/depression controls. TDI = Townsend Deprivation Index; negative scores indicate less deprivation. SD = standard deviation.

		Pop. Prev.	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)
Autoimmune Diseases (system/disease)			Possible							Probable						
Blood	Pernicious Anemia	0.10%	1,555	0.48%	58.9 (7.61)	71%	-0.85 (3.19)	13%	28.0 (5.55)	423	0.13%	60.1 (7.19)	72%	-0.99 (3.23)	12%	28.5 (5.34)
Endocrine system	Autoimmune Thyroid Disease	2.00%	859	0.26%	56.8 (7.75)	85%	-1.11 (3.05)	15%	27.4 (5.11)	607	0.19%	57.0 (7.64)	86%	-1.06 (3.03)	16%	27.8 (5.21)
	Type 1 diabetes	0.30%	2,751	0.84%	58.3 (7.80)	42%	-0.46 (3.39)	13%	30.1 (6.08)	2,292	0.70%	58.0 (7.85)	43%	-0.50 (3.39)	12%	29.9 (6.07)
Nervous system	Multiple Sclerosis	0.10%	1,683	0.52%	55.4 (7.52)	73%	-1.45 (3.01)	16%	26.9 (5.08)	1,154	0.35%	55.5 (7.45)	73%	-1.33 (3.06)	17%	26.9 (5.27)
	Myasthenia Gravis	0.02%	234	0.07%	59.2 (7.39)	56%	-0.94 (3.27)	11%	29.0 (5.44)	147	0.05%	60.1 (7.09)	48%	-1.06 (3.32)	12%	29.3 (5.18)
Digestive system	Coeliac	1.00%	2,364	0.72%	57.8 (7.79)	67%	-1.49 (2.99)	7%	25.8 (4.57)	1,260	0.39%	58.4 (7.66)	68%	-1.42 (3.03)	7%	25.8 (4.60)
	Inflammatory Bowel Disease	0.50%	5,105	1.55%	57.4 (7.92)	51%	-1.27 (3.10)	10%	27.3 (4.70)	3,538	1.08%	57.3 (7.98)	50%	-1.28 (3.07)	9%	27.2 (4.63)
Skin	Psoriasis	2.00%	5,459	1.66%	56.8 (8.01)	46%	-1.05 (3.22)	15%	28.4 (5.17)	2,759	0.84%	57.1 (8.04)	42%	-0.90 (3.28)	16%	28.7 (5.26)
Musculoskeletal system and connective tissue	Ankylosing Spondylitis	0.55%	1,344	0.41%	57.9 (7.47)	38%	-1.02 (3.21)	13%	27.8 (4.80)	413	0.13%	57.4 (7.57)	26%	-1.06 (3.22)	12%	27.9 (4.85)
	Polymyalgia Rheumatica/GCA	0.85%	1,627	0.50%	63.1 (5.16)	67%	-1.70 (2.79)	9%	28.3 (5.08)	898	0.28%	63.7 (4.58)	68%	-1.67 (2.75)	9%	28.4 (5.24)
	Psoriatic Arthritis	0.50%	1,107	0.34%	56.6 (7.48)	50%	-1.16 (3.18)	11%	29.0 (5.43)	779	0.24%	56.6 (7.52)	51%	-1.06 (3.23)	11%	29.3 (5.59)
	Rheumatoid Arthritis	1.00%	6,360	1.92%	59.5 (7.06)	67%	-0.91 (3.29)	13%	28.5 (5.53)	3,451	1.05%	59.6 (7.01)	70%	-1.08 (3.18)	12%	28.2 (5.50)
	Sjögren Syndrome	0.70%	647	0.20%	59.3 (7.10)	90%	-1.20 (3.03)	6%	27.1 (5.72)	389	0.12%	59.2 (7.26)	89%	-1.19 (3.10)	7%	27.0 (5.55)
	Systemic Lupus Erythematosus	0.10%	624	0.19%	56.7 (8.18)	84%	-1.02 (3.21)	14%	27.3 (5.65)	362	0.11%	56.6 (8.00)	86%	-0.99 (3.15)	14%	27.3 (5.82)
Any Autoimmune Disease		NA	28,479	8.08%	58.1 (7.73)	58%	-1.11 (3.17)	12%	27.9 (5.28)	16,824	4.94%	58.1 (7.73)	57%	-1.10 (3.17)	12%	28.0 (5.34)
<i>Autoimmune Controls</i>		NA	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)
Depression			Any							Stringent						
Depression		15%	65,075	21.86%	55.4 (7.86)	67%	-1.09 (3.14)	13%	27.8 (5.32)	14,625	5.92%	56.1 (7.88)	67%	-0.58 (3.35)	19%	28.9 (5.77)
<i>Depression Controls</i>		NA	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)

220

221 The prevalence of any depression was significantly higher in autoimmune cases compared to
 222 autoimmune controls ($p = 6 \times 10^{-177}$ for possible cases of any autoimmune disease versus controls, $p =$
 223 2×10^{-124} for probable cases of any autoimmune disease versus controls). The prevalence of stringent
 224 depression was significantly higher in autoimmune cases compared to autoimmune controls ($p = 3 \times 10^{-$
 225 207 for possible cases of any autoimmune disease versus controls, $p = 6 \times 10^{-163}$ for probable cases of any
 226 autoimmune disease versus controls) (Table 2).

227 Table 2: Prevalence of depression within autoimmune cases compared to autoimmune controls, stratified by
 228 possible/probable for autoimmune diseases, and any/stringent for depression cases. P-values from pairwise
 229 comparisons of depression prevalence in autoimmune cases compared to autoimmune controls are shown in brackets.

Autoimmune Trait		Depression prevalence in autoimmune traits			
		Any depression prevalence		Stringent depression prevalence	
		Possible Autoimmune	Probable Autoimmune	Possible Autoimmune	Probable Autoimmune
Autoimmune Controls		20.6%		5.1%	
Any Autoimmune Disease		28.9% (6×10^{-177})	29.5% (2×10^{-124})	10.8% (3×10^{-207})	11.5% (6×10^{-163})
Blood	Pernicious Anemia	35.8% (4×10^{-36})	33.7% (4×10^{-8})	15.2% (1×10^{-39})	16.6% (4×10^{-15})
Endocrine system	Autoimmune Thyroid Disease	35.1% (6×10^{-19})	34.7% (6×10^{-13})	13.7% (1×10^{-16})	13.4% (3×10^{-11})
	Type 1 diabetes	31.1% (3×10^{-31})	31.3% (1×10^{-27})	14.1% (5×10^{-59})	13.5% (5×10^{-43})
Nervous System	Multiple Sclerosis	39.3% (6×10^{-56})	42.5% (3×10^{-51})	16.9% (5×10^{-54})	20.0% (8×10^{-57})
	Myasthenia Gravis	33.3% (5×10^{-5})	29.2% (3×10^{-2})	14.1% (5×10^{-6})	14.8% (4×10^{-5})
Digestive system	Coeliac	27.3% (3×10^{-12})	29.8% (2×10^{-12})	8.4% (4×10^{-8})	9.5% (7×10^{-8})
	Inflammatory Bowel Disease	24.9% (6×10^{-11})	24.9% (3×10^{-8})	8.9% (8×10^{-22})	9.1% (2×10^{-17})
Skin	Psoriasis	26.8% (2×10^{-22})	28.3% (1×10^{-17})	8.7% (4×10^{-20})	9.9% (4×10^{-18})
Musculoskeletal system and connective tissue	Ankylosing Spondylitis	26.9% (5×10^{-7})	28.4% (5×10^{-4})	9.6% (7×10^{-9})	10.5% (9×10^{-5})
	Polymyalgia Rheumatica/GCA	29.3% (2×10^{-13})	27.8% (5×10^{-6})	10.8% (3×10^{-15})	10.6% (1×10^{-8})
	Psoriatic Arthritis	31.8% (3×10^{-15})	34.3% (5×10^{-16})	10.2% (1×10^{-8})	13.0% (2×10^{-13})
	Rheumatoid Arthritis	30.6% (5×10^{-62})	29.4% (6×10^{-28})	12.7% (3×10^{-92})	12.1% (1×10^{-45})
	Sjögren Syndrome	40.7% (4×10^{-25})	41.9% (1×10^{-17})	18.9% (2×10^{-28})	18.9% (7×10^{-18})
	Systemic Lupus Erythematosus	40.2% (2×10^{-25})	44.5% (2×10^{-22})	18.8% (6×10^{-30})	22.2% (8×10^{-27})


230 The prevalence of possible cases of any autoimmune disease was significantly higher in depression cases
 231 compared to depression controls ($p = 6 \times 10^{-177}$ for any depression versus controls, $p = 3 \times 10^{-207}$ for
 232 stringent depression versus controls). The prevalence of probable cases of any autoimmune disease was
 233 significantly higher in depression cases compared to depression controls ($p = 2 \times 10^{-124}$ for any depression
 234 versus controls, $p = 6 \times 10^{-163}$ for stringent depression versus controls) (Table 3).

235 Table 3: Prevalence of autoimmune diseases within depression cases compared to depression controls, stratified by
 236 possible/probable for autoimmune diseases, and stringent/any for depression cases. P-values from pairwise
 237 comparisons of autoimmune prevalence in depression cases compared to depression controls are shown in brackets.

Autoimmune Trait		Autoimmune prevalence in depression					
		Possible autoimmune prevalence			Probable autoimmune prevalence		
		Any Depression	Stringent Depression	Depression Controls	Any Depression	Stringent Depression	Depression Controls
Any Autoimmune Disease		10.48% (6×10^{-177})	14.27% (3×10^{-207})	6.94%	6.59% (2×10^{-124})	9.48% (6×10^{-163})	4.19%
Blood	Pernicious Anemia	0.77% (4×10^{-36})	1.17% (1×10^{-39})	0.36%	0.19% (4×10^{-8})	0.35% (4×10^{-15})	0.10%
Endocrine system	Autoimmune Thyroid Disease	0.41% (6×10^{-19})	0.58% (1×10^{-16})	0.20%	0.28% (6×10^{-13})	0.39% (3×10^{-11})	0.14%
	Type 1 diabetes	1.20% (3×10^{-31})	2.07% (5×10^{-59})	0.69%	1.02% (1×10^{-27})	1.65% (5×10^{-43})	0.58%
Nervous System	Multiple Sclerosis	0.87% (6×10^{-56})	1.31% (5×10^{-54})	0.35%	0.63% (3×10^{-51})	1.02% (8×10^{-57})	0.22%
	Myasthenia Gravis	0.11% (5×10^{-5})	0.17% (5×10^{-6})	0.05%	0.06% (3×10^{-2})	0.12% (4×10^{-5})	0.04%
Digestive system	Coeliac	0.92% (3×10^{-12})	1.08% (4×10^{-8})	0.64%	0.54% (2×10^{-12})	0.64% (7×10^{-8})	0.33%
	Inflammatory Bowel Disease	1.82% (6×10^{-11})	2.56% (8×10^{-22})	1.43%	1.28% (3×10^{-8})	1.85% (2×10^{-17})	1.00%
Skin	Psoriasis	2.05% (2×10^{-22})	2.55% (4×10^{-20})	1.46%	1.10% (1×10^{-17})	1.47% (4×10^{-18})	0.73%
Musculoskeletal system and connective tissue	Ankylosing Spondylitis	0.52% (5×10^{-7})	0.72% (7×10^{-9})	0.37%	0.17% (5×10^{-4})	0.25% (9×10^{-5})	0.11%
	Polymyalgia Rheumatica/GCA	0.66% (2×10^{-13})	0.93% (3×10^{-15})	0.42%	0.35% (5×10^{-6})	0.51% (1×10^{-8})	0.23%
	Psoriatic Arthritis	0.50% (3×10^{-15})	0.58% (1×10^{-8})	0.28%	0.38% (5×10^{-16})	0.51% (2×10^{-13})	0.19%
	Rheumatoid Arthritis	2.66% (5×10^{-62})	4.14% (3×10^{-92})	1.59%	1.42% (6×10^{-28})	2.23% (1×10^{-45})	0.89%
	Sjögren Syndrome	0.34% (4×10^{-25})	0.55% (2×10^{-28})	0.13%	0.21% (1×10^{-17})	0.33% (7×10^{-18})	0.08%
	Systemic Lupus Erythematosus	0.36% (2×10^{-25})	0.59% (6×10^{-30})	0.14%	0.23% (2×10^{-22})	0.39% (8×10^{-27})	0.08%

238

239 Testing for same-trait PRS associations, PRS for MDD were significantly associated with any depression
 240 case-status ($p < 5 \times 10^{-324}$, $R^2 = 1.48\%$) and stringent depression case-status ($p = 2 \times 10^{-228}$, $R^2 = 2.23\%$). PRS
 241 for autoimmune diseases were significantly associated with both possible and probable case-control
 242 status for the corresponding diseases (Figure 2). The variance in liability, R^2 , explained by PRS was higher
 243 in strictly-defined compared to liberally-defined phenotypes. Most results were highly significant ($p <$
 244 6×10^{-29}), except myasthenia gravis ($p < 7 \times 10^{-3}$), which has the smallest sample size of less than 250 cases,
 245 and psoriatic arthritis ($p < 3 \times 10^{-6}$) where the discovery GWAS has only 1430 cases.



246


247 Figure 2: Variances in autoimmune liability explained by PRS for the corresponding autoimmune diseases. The number
 248 of cases are shown at the top of the plot (possible = blue, probable = red). P-values are shown atop each bar.

249

250 In the prediction of depression from autoimmune PRS (Figure 3), the PRS for myasthenia gravis were
 251 significantly associated with case-status for any depression ($p = 5.2 \times 10^{-5}$, $R^2 = 0.01\%$) and stringent
 252 depression ($p = 1.6 \times 10^{-5}$, $R^2 = 0.04\%$). PRS for psoriasis were significantly associated with case-status for

253 any depression ($p = 8.7 \times 10^{-6}$, $R^2 = 0.01\%$). No other autoimmune disease PRS predicted depression case-
 254 control status, and no sex-specific analyses met the Bonferroni-corrected threshold for significance. The
 255 R^2 values for variance explained in depression by autoimmune PRS are all very low, at $<0.1\%$, and
 256 substantially lower than the R^2 for autoimmune diseases (Figure 2).

257



258

259 Figure 3: Variances in depression liability explained by PRS for autoimmune diseases (x-axis). Asterisks denote
 260 associations with p -values $< 7.1 \times 10^{-5}$, meeting Bonferroni correction. Number of cases for depression phenotypes: Any
 261 (combined) = 65,075; Any (female) = 43,413; Any (male) = 21,662; Stringent (combined) = 14,625; Stringent (female) =
 262 9,738; Stringent (male) = 4,887.

263


264 Genetic liability for MDD was significantly associated with six autoimmune diseases: coeliac,
 265 inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and type 1 diabetes (all
 266 p -values $< 5.8 \times 10^{-5}$, R^2 range between 0.06% and 0.27%) (Figure 4). For three, the association with MDD
 267 was observed in probable and possible cases (psoriasis, rheumatoid arthritis and type 1 diabetes). For
 268 coeliac and inflammatory bowel disease, the association was only in possible cases. For psoriatic arthritis,

269 the association was only in probable cases. For all significant associations observed, higher PRS increased
270 risk for the outcome phenotype, except for coeliac, where higher MDD PRS was associated with reduced
271 risk ($p = 6 \times 10^{-8}$, $R^2 = 0.17\%$, $\beta = -0.11$, $SE = 0.02$, in the combined sample).

272 Sex-specific associations were observed, primarily in female autoimmune cases (coeliac, inflammatory
273 bowel disease, type 1 diabetes and rheumatoid arthritis, all $p < 4.5 \times 10^{-5}$). Association in males was
274 observed in psoriasis (possible cases, $p = 5.8 \times 10^{-5}$), and in rheumatoid arthritis (possible cases, $p = 1.6 \times 10^{-5}$).
275 The most consistent results were observed in rheumatoid arthritis, where the sample size was largest,
276 with five of the six analyses reaching Bonferroni threshold for significance (all $p < 4.5 \times 10^{-5}$, R^2 range
277 between 0.07% and 0.1%). However, there was no evidence for a significant interaction between sex
278 and PRS in the combined samples of men and women (all $p > 0.02$), indicating that sex-specific
279 associations were generally influenced by sample size.

280 Full results of each test are shown in Supplementary Tables 2 to 5 and Supplementary Figures 1 to 4.

281



282

283 Figure 4: Variances in autoimmune liability (x-axes) explained by PRS for MDD. Asterisks denote associations with p-
 284 values <math> < 7.1 \times 10^{-5}</math>, meeting Bonferroni correction. Number of cases for the autoimmune diseases are given in Table 1.

285

286 Power analyses showed that, in the prediction of any depression from autoimmune PRS, there was 80%
 287 power to detect associations assuming modest levels of underlying genetic correlation (rG) below 0.15.
 288 There were two exceptions; multiple sclerosis and myasthenia gravis, where the underlying rG would
 289 need to approach ~0.3 to achieve 80% power (Supplementary Figure 6). In the prediction of possible

290 autoimmune diseases from depression PRS, there was 80% power to detect associations assuming r_G
291 < 0.1 , again with the exception myasthenia gravis, where an $r_G \sim 0.18$ would be required to achieve 80%
292 power (Supplementary Figure 7).

293 Discussion

294 Motivated by epidemiological findings of a bi-directional relationship between depression and
295 autoimmune diseases, we tested for evidence of pleiotropy between traits, adopting both liberal and
296 strict phenotyping approaches to define cases in the UKB. We showed modest association of PRS from
297 autoimmune diseases with MDD, and slightly stronger associations of MDD PRS with autoimmune
298 diseases. These observations suggest only a minor component of observed comorbidity is due to shared
299 genetics between depression and autoimmune diseases.

300 We made three key observations: 1) Phenotypic variance explained by PRS for corresponding traits was
301 higher in strictly-defined than liberally-defined cases, indicating more rigorous phenotyping improved
302 the validity of autoimmune and depression cases; 2) The phenotypic overlap between depression and
303 autoimmune diseases was consistent with the literature – depression was more common in individuals
304 with autoimmune diseases, and vice-versa; 3) Cross-trait PRS analyses identified significant associations
305 between depression and some autoimmune diseases, but with effect sizes indicating the existence of a
306 shared biological component of modest effect on the observed comorbidity.

307 Our phenotyping approach for autoimmune diseases used both strictly-defined and liberally-defined
308 cases, integrating the multiple sources of UKB data. PRS constructed for eight autoimmune diseases
309 predicted case-control status, increasing confidence in the robustness of case definition. The phenotypic
310 variance explained was higher in strictly-defined cases, potentially reflecting greater specificity;
311 identifying individuals with multiple endorsements for a disease (e.g. hospital admission and prescription

312 medication) reduces the probability of misclassifying controls as cases. Conversely, the criteria for
313 liberally-defined cases increases sample size, but may induce misclassification of controls as cases.

314 For each of the fourteen autoimmune diseases considered, cases had higher frequencies of depression
315 than controls, recapitulating the effect observed in epidemiological studies. Similarly, the prevalence of
316 each autoimmune disease was significantly higher in depression cases compared to controls. Prevalence
317 estimates reported here are cross-sectional, and we lack information on the temporal relationship
318 between traits.

319 The findings from cross-trait PRS analyses identified significant associations, although observed effect
320 sizes were small, ranging between $R^2 = 0.01\%$ and 0.27% . For three traits, we observed significant
321 associations in liberally-defined, but not strictly-defined cases (psoriasis PRS was associated with any
322 depression, MDD PRS was associated with possible coeliac and inflammatory bowel disease). In contrast,
323 MDD PRS was associated with probable, but not possible, psoriatic arthritis, suggesting misclassification
324 in possible cases. Misclassification bias may vary across diseases; some autoimmune diseases may be
325 more prone to misclassification with other autoimmune diseases, whilst other diagnoses may misclassify
326 with non-inflammatory conditions. For example, osteoarthritis (non-inflammatory) may misclassify as
327 psoriatic arthritis in the absence of multiple-item endorsement to increase diagnosis validity.

328 Cross-trait PRS analyses identified some sex-dependent associations. MDD PRS were associated with
329 psoriasis in males, and MDD PRS were associated with coeliac, inflammatory bowel disease and type 1
330 diabetes in females. However, sensitivity analyses revealed no evidence for significant interactions
331 between PRS and sex in the combined sample, indicating that sex-dependent associations were generally

332 driven by different sample sizes in sex-stratified analyses. Rheumatoid arthritis was the most common
333 autoimmune disease and showed the most consistency in cross-trait associations; MDD PRS were
334 significantly associated with rheumatoid arthritis in all case groups, except probable males. This is in
335 contrast with Euesden, et al.¹⁰, who found no evidence for association between PRS for depression and
336 risk for rheumatoid arthritis, but in a substantially smaller sample of 226 cases. Liu, et al.⁶ also found no
337 evidence for association between a composite mental health disorder PRS and risk for autoimmune
338 diseases, but also in a smaller sample of 1,383 individuals with any of seven autoimmune diseases.
339 However, a composite PRS for autoimmune diseases did show weak association with case-control status
340 in a sample of 43,902 individuals with any of six mental health disorders in the Liu, et al.⁶ study. This
341 highlights the importance of sample size, and our study benefits from the scale of the UKB, where power
342 calculations indicated our investigation was able to detect even modest pleiotropic effects. However,
343 there were exceptions for rare autoimmune diseases, where larger samples would be required to reject
344 the presence of a weak genetic correlation with depression.

345 The weak genetic contribution suggests that another mechanism may be driving or contributing to the
346 bi-directional relationship between autoimmune diseases and depression⁴⁴. Inflammatory factors
347 underlying some cases of depression could provide a common biological pathogenesis with autoimmune
348 diseases. Lynall, et al.⁴⁵ observed increased immune cell counts in depression cases compared to
349 controls, and identified a sub-group of cases with elevated inflammatory markers who presented with
350 more severe depression than uninflamed cases. In our data, we considered whether R^2 values mirrored
351 the inflammatory burden of autoimmune diseases, recognizing that some diagnoses have much higher
352 levels of systemic inflammation (e.g. IBD or RA) than others (e.g. Coeliac). Although subtle differences

353 were present, in absolute terms variation was small and it was not possible to infer a ‘dose-response’
354 effect between autoimmune disease PRS and depression.

355 Environmental risk factors such as BMI and childhood maltreatment increase risk of both depression and
356 autoimmune diseases and would contribute to the bi-directional effect^{46,47}. Similarly, some treatments
357 for depression (antidepressants) and autoimmune diseases (steroids) are obesogenic and may increase
358 comorbidity. Diagnosis with autoimmune disease increases risk of depression due to psychological
359 factors in adjusting to a chronic disorder and changes in behaviour such as reduced exercise. Health
360 related behaviours that are elevated in depression (smoking, poor diet and reduced physical activity)
361 increase risk for autoimmune diseases. These mechanisms may not be independent of joint genetic
362 contributors. For example, shared inflammatory mechanisms would lead to horizontal pleiotropy, where
363 genetic variants directly affect both disorders, and vertical pleiotropy can arise through environmental
364 risk factors where genetic variation influences one trait through mediation on another trait.

365 Limitations

366 A healthy volunteer bias has been observed in the UKB⁴⁸, and is a noted limitation of the study. However,
367 it has been proposed that this bias may attenuate, but not invalidate, exposure-outcome relationships⁴⁹.
368 A further limitation of the ability to extrapolate our results is the lack of representation in individuals of
369 diverse ancestries. The literature has demonstrated attenuation in PRS analyses where training and
370 target samples are drawn from different ancestral populations⁵⁰, highlighting the need to perform GWAS
371 in diverse ancestries. This limitation may have broader implications than would otherwise be the case

372 for some conditions, such as SLE, which disproportionately affect individuals of African and Asian
373 ancestry.

374 Although every effort has been made to address the potential for misclassification bias through the
375 criteria for multiple-item endorsements in strictly-defined cases, the approach remains imperfect. The
376 impact of misclassification depends on the effect directionality, and it is possible that mis-estimation of
377 associations has occurred. However, it is our contention that even misclassification of moderate size
378 would have only marginal impacts on the inferences made above.

379 [Conclusions](#)

380 We identified cases and controls for depression and fourteen autoimmune diseases in the UKB, using
381 both strict and liberal phenotyping. PRS analyses indicated that strict phenotyping improved the validity
382 of cases, demonstrating that multiple UKB variables can be leveraged to increase specificity. Consistent
383 with the literature, we found that depression was enriched in autoimmune cases, and vice-versa. Despite
384 having power to detect subtle pleiotropic effects, we found little evidence that shared genetic factors
385 have a meaningful influence on the observed co-occurrence of depression and autoimmune diseases in
386 the UK Biobank. The limited shared genetic component will make only a modest contribution to the bi-
387 directional disease risks, and shared environmental factors, including health-related characteristics and
388 stressful life events, may be important. Future studies leveraging phenotypic, genetic, diagnostic,
389 treatment and environmental risk factors may be necessary to unpick the mechanisms contributing to
390 shared risks for autoimmune diseases and depression. In particular, future research should consider the

391 psychological impacts of autoimmune disease while remaining cognizant of the need to consider and
392 treat the two diseases in parallel.

393 Funding

394 This work was supported by the UK Medical Research Council (PhD studentship to KPG; grant
395 MR/N015746/1). This paper represents independent research part-funded by the National Institute for
396 Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation
397 Trust and King's College London. The views expressed are those of the authors and not necessarily those
398 of the NHS, the NIHR or the Department of Health and Social Care.

399 Acknowledgements

400 We thank participants and scientists involved in making the UK Biobank resource available
401 (<http://www.ukbiobank.ac.uk/>). The UKB received ethical approval from the North West - Haydock
402 Research Ethics Committee (reference 16/NW/0274). This study was conducted under application
403 number 18177. We thank the research participants and employees of 23andMe for making this work
404 possible. The MDD GWAS summary statistics results from 23andMe were available through a Data
405 Transfer Agreement between 23andMe, Inc., and King's College, London. Only summary statistics were
406 shared with no individual level data. 23andMe participants provided informed consent and participated
407 in the research online. The 23andMe protocol was approved by an external Association for the
408 Accreditation of Human Research Protection Programs accredited Institutional Review Board, Ethical
409 and Independent Review Services. Participants were included in the analysis on the basis of consent
410 status as checked at the time data analyses were initiated. Statistical analyses were carried out on the
411 King's Health Partners High Performance Compute Cluster funded with capital equipment grants from
412 the GSTT Charity (TR130505) and Maudsley Charity (980). We thank Nick Dand, Satveer Mahil and

413 Catherine Smith of King's College London for their contribution in identifying medications used in the
414 treatment of Psoriasis in the UKB.

415 [Data Availability](#)

416 Available from UK Biobank subject to standard procedures (www.ukbiobank.ac.uk). The full GWAS
417 summary statistics for the 23andMe discovery data set will be made available through 23andMe to
418 qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe
419 participants. Please visit <https://research.23andme.com/collaborate/#publication> for more information
420 and to apply to access the data.

421 [Author contributions](#)

422 Conceptualisation and study design: KPG, CML, JG, PFO. Analysis and manuscript: KPG. Analytical
423 consultation and interpretation: CML, JG, PFO, JRIC. UKB data curation and management: JRIC, KPG.
424 Genetic data preparation: JRIC, KPG. Project supervisors: CML, JG, PFO. All authors critically edited the
425 paper.

426 [Declaration of Interest](#)

427 CML is a member of the SAB for Myriad Neuroscience. The remaining authors declare no competing
428 interests.

429 References

- 430 1. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al.
431 Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders A
432 Nationwide Study. *JAMA Psychiatry*. American Medical Association; 2013
433 Aug;70(8):812–20.
- 434 2. Anderson RJ, Freedberg KA, Clouse RE, Lustman PJ. The Prevalence of Comorbid
435 Depression in Adults With Diabetes. *Diabetes Care*. 2001 Jun;24(6):1069–78.
- 436 3. Patten SB, Beck CA, Williams JVA, Barbui C, Metz LM. Major depression in multiple
437 sclerosis: A population-based perspective. *Neurology*. 61st ed. 2003 Dec;:1524–7.
- 438 4. Kurina L, Goldacre M, Yeates D, Gill L. Depression and anxiety in people with
439 inflammatory bowel disease. *Journal of Epidemiology and Community Health*. BMJ
440 Publishing Group; 2001 Oct 1;55(10):716–20.
- 441 5. Andersson NW, Gustafsson LN, Okkels N, Taha F, Cole SW, Munk-Jorgensen P, et al.
442 Depression and the risk of autoimmune disease: a nationally representative, prospective
443 longitudinal study. *Psychol Med*. Cambridge University Press; 2015 Dec;45(16):3559–
444 69.
- 445 6. Liu X, Nudel R, Thompson WK, Appadurai V, Schork AJ, Buil A, et al. Genetic factors
446 underlying the bidirectional relationship between autoimmune and mental disorders –
447 findings from a Danish population-based study. *Brain, Behavior, and Immunity*.
448 Academic Press; 2020 Jun 11.
- 449 7. Glanville KP, Coleman JRI, Hanscombe KB, Euesden J, Choi SW, Purves KL, et al.
450 Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly
451 Associated With Depression. *Biological Psychiatry*. Elsevier; 2020 Mar 1;87(5):419–30.
- 452 8. Nudel R, Benros ME, Krebs MD, Allesøe RL, Lemvig CK, Bybjerg-Grauholm J, et al.
453 Immunity and mental illness: findings from a Danish population-based immunogenetic
454 study of seven psychiatric and neurodevelopmental disorders. *European Journal of*
455 *Human Genetics*. Nature Publishing Group; 2019 Apr 11;8(1):1.
- 456 9. Hu X, Daly M. What have we learned from six years of GWAS in autoimmune diseases,
457 and what is next? *Current Opinion in Immunology*. Elsevier Current Trends; 2012 Oct
458 1;24(5):571–5.
- 459 10. Euesden J, Danese A, Lewis CM, Maughan B. A bidirectional relationship between
460 depression and the autoimmune disorders - New perspectives from the National Child
461 Development Study. *PLOS ONE*. Public Library of Science; 2017 Mar;12(3):1–14.

- 462 11. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al.
463 Genome-wide association analyses identify 44 risk variants and refine the genetic
464 architecture of major depression. *Nature Genetics*. Nature Publishing Group; 2018
465 May;50:668–81.
- 466 12. Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Han
467 B, Wu Y, Mignot E, Ollila HM, et al. Cross-disorder analysis of schizophrenia and 19
468 immune-mediated diseases identifies shared genetic risk. *Human Molecular Genetics*.
469 2019 Jun 18.
- 470 13. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
471 resource with deep phenotyping and genomic data. *Nature*. Nature Publishing Group;
472 2018 Oct 1;562(7726):203–9.
- 473 14. World Health Organization. *International Classification of Diseases (10th Edition)*.
474 Geneva: World Health Organisation; 1992.
- 475 15. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in
476 UK Biobank – development, implementation and results from an online questionnaire
477 completed by 157 366 participants: a reanalysis. *BJPsych Open*. Cambridge University
478 Press; 2020 Mar 1;6(2):e18.
- 479 16. Glanville KP, Coleman JR, Howard DM, Pain O, Hanscombe KB, Jermy B, et al. Multiple
480 measures of depression to enhance validity of Major Depressive Disorder in the UK
481 Biobank. *medRxiv*. Cold Spring Harbor Laboratory Press; 2020 Sep
482 22;:2020.09.18.20196451.
- 483 17. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and
484 Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank:
485 Cross-Sectional Study of 172,751 Participants. Potash JB, editor. *PLOS ONE*. 2013 Nov
486 25;8(11):e75362.
- 487 18. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
488 PLINK: rising to the challenge of larger and richer datasets. *GigaScience* [Internet]. 2015
489 Feb 25;4(1):559. Available from: www.cog-genomics.org/plink/1.9/
- 490 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
491 relationship inference in genome-wide association studies. *Bioinformatics*. 2010 Nov
492 15;26(22):2867–73.
- 493 20. Choi SW. `choishingwan/GreedyRelated`: Function update. 2020 Mar 4.
- 494 21. Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank-
495 scale genotype datasets. *Bioinformatics*. 2017 Sep 1;33(17):2776–8.

- 496 22. R Development Core Team. R: A language and environment for statistical computing
497 [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available from:
498 <http://www.R-project.org>
- 499 23. Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple
500 common variants for celiac disease influencing immune gene expression. *Nature*
501 *Genetics*. Nature Publishing Group; 2010 Apr 1;42(4):295–302.
- 502 24. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association
503 analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight
504 shared genetic risk across populations. *Nature Genetics*. Nature Publishing Group; 2015
505 Sep 1;47(9):979–86.
- 506 25. The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case
507 Control Consortium 2. Genetic risk and a primary role for cell-mediated immune
508 mechanisms in multiple sclerosis. *Nature*. Nature Publishing Group; 2011 Aug
509 1;476(7359):214–9.
- 510 26. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, et al. A Genome-
511 Wide Association Study of Myasthenia Gravis. *JAMA neurology*. *JAMA Neurol*; 2015 Apr
512 1;72(4):396–404.
- 513 27. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
514 meta-analysis characterizes genetic architecture for common psoriasis associated
515 variants. *Nature Communications*. Nature Publishing Group; 2017 May 24;8(1):1–8.
- 516 28. Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, et al. Genetic
517 variation at the glycosaminoglycan metabolism pathway contributes to the risk of
518 psoriatic arthritis but not psoriasis. *Annals of the Rheumatic Diseases*. BMJ Publishing
519 Group Ltd; 2019 Mar 1;78(3):355–64.
- 520 29. Okada Y, Di Wu, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis
521 contributes to biology and drug discovery. *Nature*. Nature Publishing Group; 2014 Feb
522 1;506(7488):376–81.
- 523 30. Bentham J, Morris DL, Graham DSC, Pinder CL, Tomblinson P, Behrens TW, et al.
524 Genetic association analyses implicate aberrant regulation of innate and adaptive
525 immunity genes in the pathogenesis of systemic lupus erythematosus. *Nature Genetics*.
526 Nature Publishing Group; 2015 Dec 1;47(12):1457–64.
- 527 31. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
528 - PubMed - NCBI. *GigaScience*. 2019 Jul 15;8(7):2091.
- 529 32. Andres E, Serraj K. Optimal management of pernicious anemia. *Journal of blood*
530 *medicine*. *J Blood Med*; 2012;3:97–103.

- 531 33. Simmonds MJ, Gough SCL. Unravelling the genetic complexity of autoimmune thyroid
532 disease: HLA, CTLA-4 and beyond. *Clinical and Experimental Immunology*. Wiley-
533 Blackwell; 2004 Apr 1;136(1):1–10.
- 534 34. Bradfield JP, Qu H-Q, Wang K, Zhang H, Sleiman PM, Kim CE, et al. A Genome-Wide
535 Meta-Analysis of Six Type 1 Diabetes Cohorts Identifies Multiple Associated Loci.
536 McCarthy MI, editor. *PLoS Genet*. Public Library of Science; 2011 Sep
537 29;7(9):e1002293.
- 538 35. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. *BMJ*. British Medical Journal
539 Publishing Group; 2012 Dec 21;345(dec21 3):e8497–7.
- 540 36. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
541 meta-analysis characterizes genetic architecture for common psoriasis associated
542 variants. - PubMed - NCBI. *Nature Communications*. 2017 May 24;8:15382.
- 543 37. International Genetics of Ankylosing Spondylitis Consortium (IGAS). Identification of
544 multiple risk variants for ankylosing spondylitis through high-density genotyping of
545 immune-related loci. *Nature Genetics*. Nature Publishing Group; 2013 Jul 1;45(7):730–8.
- 546 38. Partington RJ, Muller S, Helliwell T, Mallen CD, Sultan AA. Incidence, prevalence and
547 treatment burden of polymyalgia rheumatica in the UK over two decades: a population-
548 based study. *Annals of the Rheumatic Diseases*. BMJ Publishing Group Ltd; 2018 Dec
549 1;77(12):1750–6.
- 550 39. Humphreys JH, Verstappen SMM, Hyrich KL, Chipping JR, Marshall T, Symmons DPM.
551 The incidence of rheumatoid arthritis in the UK: comparisons using the 2010
552 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from
553 the Norfolk Arthritis Register. *Annals of the Rheumatic Diseases*. BMJ Publishing Group
554 Ltd; 2013 Aug 1;72(8):1315–20.
- 555 40. for UK Primary Sjögren's Syndrome Registry, Lessard CJ, Li H, Adrianto I, Ice JA,
556 Rasmussen A, et al. Variants at multiple loci implicated in both innate and adaptive
557 immune responses are associated with Sjögren's syndrome. *Nature Genetics*. *Nat*
558 *Genet*; 2013 Oct 6;45(11):1284–92.
- 559 41. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and
560 prevalence of systemic lupus erythematosus in the UK, 1999–2012. *Annals of the*
561 *Rheumatic Diseases*. BMJ Publishing Group Ltd; 2016 Jan 1;75(1):136–41.
- 562 42. Luigi Palla FD. A Fast Method that Uses Polygenic Scores to Estimate the Variance
563 Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting a
564 Trait. *Am J Hum Genet*. Elsevier; 2015 Aug 6;97(2):250–9.
- 565 43. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working
566 Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes

- 567 confounding from polygenicity in genome-wide association studies. *Nature Genetics*.
568 2015 Mar;47(3):291–5.
- 569 44. Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al.
570 Comorbid depression in medical diseases. *Nat Rev Dis Primers*. Nature Publishing
571 Group; 2020 Aug 20;6(1):1–22.
- 572 45. ME L, L T, J B, J C, de Boer P, Mondelli V, et al. Peripheral Blood Cell-Stratified
573 Subgroups of Inflamed Depression. *Biological Psychiatry*. *Biol Psychiatry*; 2020 Jul
574 15;88(2):185–96.
- 575 46. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative
576 Childhood Stress and Autoimmune Diseases in Adults. *Psychosomatic Medicine*. 2009
577 Feb;71(2):243–50.
- 578 47. Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of
579 multiple adverse childhood experiences on health: a systematic review and meta-
580 analysis. *The Lancet Public Health*. Elsevier; 2017 Aug 1;2(8):e356–66.
- 581 48. A F, T J L, C S, N D, L A, T S, et al. Comparison of Sociodemographic and Health-
582 Related Characteristics of UK Biobank Participants With Those of the General
583 Population. *American Journal of Epidemiology*. *Am J Epidemiol*; 2017 Nov
584 1;186(9):1026–34.
- 585 49. Batty GD, Gale C, Kivimaki M, Deary I, Bell S. Generalisability of Results from UK
586 Biobank: Comparison With a Pooling of 18 Cohort Studies. *medRxiv*. Cold Spring Harbor
587 Laboratory Press; 2019 Aug 13;:19004705.
- 588 50. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of
589 polygenic risk score usage and performance in diverse human populations. *Nature*
590 Communications. Nature Publishing Group; 2019 Jul 25;10(1):1–9.
- 591